Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Locus Pharmaceuticals has appointed Jamie Freedman as its new president and CEO. Dr Freedman will succeed Joseph Reiser, who is retiring but will remain on the board of directors.
Subscribe to our email newsletter
Dr Freedman joined Locus in January, 2008 as chief medical officer, and vice president of clinical research and regulatory affairs. Prior to joining Locus, Dr Freedman was at Merck Research Labs for five years where he held a variety of positions of increasing responsibility within clinical research.
Dr Freedman received MD and PhD degrees from Tufts University, and trained in medicine and hematology-oncology at University of California, San Francisco and Harvard, respectively.
Brendan Leary, chairman of the board at Locus, said: “We are very pleased to have realized a strong internally derived leadership change for Locus. This is a tribute to the experienced team that Dr Reiser built at the company, and we are appreciative for his leadership and commitment over the years.”